Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 73.2%

Neg 73.2% Neu 0% Pos 0%

Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $7 to $5.

Comments

No comments yet. Be the first!